Valneva's Lyme disease
vaccine candidate - VLA15
Valneva has developed a multivalent, protein subunit based vaccine candidate against Lyme disease.
In December 2016, Valneva initiated a Phase I trial in the US and Europe, following clearance from the Food & Drug Administration (FDA) and the Belgian authorities, that will include 180 subjects. The first patient was vaccinated at the end of January 2017.
Pre-clinical data showed that this vaccine candidate has the potential for protection against the majority of Borrelia species pathogenic for humans (Source
In 2017, the company will advance the Phase I trial of its Lyme vaccine candidate and expects to accelerate the program´s progression towards Phase II.
Valneva’s program is the only active vaccine development program for Lyme disease in the pharmaceutical industry.
This program is supported by the Vienna Business Agency.